23andMe, Inc. is the leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service® enables individuals to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/12 | $50,000,000 | Series D |
MPM Capital Sergey Brin Yuri Milner | undisclosed |
| 10/17/15 | $115,000,000 | Series E |
Casdin Capital Illumina, Inc MPM Capital WuXi Healthcare Ventures Xfund | undisclosed |
| 09/12/17 | $250,000,000 | Growth |
Altimeter Capital Casdin Capital Fidelity Management & Research Company The Wallenberg Foundation | undisclosed |
